Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00583596 · ClinicalTrials.gov registry record · NA
Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 436
- Enrollment target
NCT00583596: Completed NA study, sponsored by Abbott Medical Devices.
NCT00583596 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 436 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00583596, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 436 participants
- Enrollment target
Study Summary
AGA-004 - The objective of the study is to determine safety, effectiveness and clinical utility of the AMPLATZER Duct Occluder in patients with patent ductus arteriosus. AGA-007 - The objective of this study is to evaluate the long term safety and effectiveness issues that may not have have been adequately addressed during AGA-004.
Interventions
- DEVICE Device closure with AMPLATZER Duct Occluder
- OTHER Objective Performance Criteria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 436 participants |
| Start Date | 1999-10 |
| Est. Completion | 2009-02 |
| Phase | NA |
What the finished NCT00583596 record still lists
NCT00583596 is an interventional study that assigns participants to a tested intervention. The registered 436 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 2 interventions - of which Device closure with AMPLATZER Duct Occluder is the first listed.
NCT00583596 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00583596 about?
NCT00583596 is a clinical study titled "Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder". AGA-004 - The objective of the study is to determine safety, effectiveness and clinical utility of the AMPLATZER Duct Occluder in patients with patent ductus arteriosus. AGA-007 - The objective of this study is to evaluate the long term safety and effectiveness issues that may not have have been ade...
What is the current status of trial NCT00583596?
This trial is currently completed. It is a NA study. The enrollment target is 436 participants. The study started on 1999-10. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00583596?
The interventions under investigation include: Device closure with AMPLATZER Duct Occluder (DEVICE), Objective Performance Criteria (OTHER).
Who is sponsoring clinical trial NCT00583596?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00583596's enrollment target sits among peer trials
436 235th of 2000 higher than 1,766 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02622542 · 436 participants · NA
ACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy
- NCT05918211 · 436 participants · Phase 3
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
- NCT06966479 · 436 participants · Phase 2
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
- NCT07318493 · 436 participants · NA
Antiseptic-Coated Sutures and Pancreatic Fistula Risk After Pancreatoduodenectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia